id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-317820-od9l7p1r	Goker Bagca, Bakiye	Overview of the COVID-19 and JAK/STAT Pathway Inhibition: Ruxolitinib Perspective	2020-06-20		.txt	text/plain	3961	233	41	The virus, which is the cause of the COVID-19 was named as Severe Acute Respiratory Syndromerelated Coronavirus (SARS-CoV-2) by Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (Figure 1a) . As an expected result of SARS-CoV-2 infection, it was reported cytokine storm syndrome triggered by the dysregulated immunity in numerous patients. There are clinical studies including baricitinib, tofacitinib, and ruxolitinib JAK inhibitors against cytokine storm caused by COVID-19. It is reported that tocilizumab which is an approved IL6 receptor antagonist, treatment reduced cytokine release syndrome symptoms in severe patients COVID-19 [66] . It is reported that the usage of ruxolitinib suppresses cytokine levels and JAK/STAT pathway in Epstein-Barr Virus (EBV) -associated hemophagocytic lymphohistiocytosis [71] . In this context, it is clear that ruxolitinib, which is used especially in older age patients, has an important potential in overcoming complications that are caused by over activation of the immune system which is triggered through JAK/STAT signaling pathway.	./cache/cord-317820-od9l7p1r.txt	./txt/cord-317820-od9l7p1r.txt